These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

670 related items for PubMed ID: 11004330

  • 1. Utility of fluorine-18-fluorodeoxyglucose positron emission tomography in differentiated thyroid carcinoma with negative radioiodine scans and elevated serum thyroglobulin levels.
    Muros MA, Llamas-Elvira JM, Ramírez-Navarro A, Gómez MJ, Rodríguez-Fernández A, Muros T, López de la Torre M, Becerra A, Carreras JL.
    Am J Surg; 2000 Jun; 179(6):457-61. PubMed ID: 11004330
    [Abstract] [Full Text] [Related]

  • 2. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
    Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, Rosai J, Robbins RJ.
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
    [Abstract] [Full Text] [Related]

  • 3. Positron emission tomography with F-18-deoxyglucose in patients with differentiated thyroid carcinoma, elevated thyroglobulin levels, and negative iodine scans.
    Altenvoerde G, Lerch H, Kuwert T, Matheja P, Schäfers M, Schober O.
    Langenbecks Arch Surg; 1998 Apr; 383(2):160-3. PubMed ID: 9641890
    [Abstract] [Full Text] [Related]

  • 4. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
    Lind P, Kohlfürst S.
    Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
    [Abstract] [Full Text] [Related]

  • 5. Value of the negative PET-FDG in the middle term follow-up of differentiated thyroid cancer in patients with negative 131 I-Na scan and elevated thyroglobulin serum levels.
    Pachón-Garrudo VM, Cuenca-Cuenca JI, Ruiz-Franco-Baux J, Borrego-Dorado I, Tirado-Hospital JL, Navarro-González E, Vázquez-Albertino R.
    Rev Esp Med Nucl Imagen Mol; 2012 Jul; 31(6):315-21. PubMed ID: 23084014
    [Abstract] [Full Text] [Related]

  • 6. Preoperative diagnostic value of [(18)F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma.
    Frilling A, Tecklenborg K, Görges R, Weber F, Clausen M, Broelsch EC.
    Ann Surg; 2001 Dec; 234(6):804-11. PubMed ID: 11729387
    [Abstract] [Full Text] [Related]

  • 7. F18-fluorodeoxyglucose positron emission tomography in detecting metastatic papillary thyroid carcinoma with elevated human serum thyroglobulin levels but negative I-131 whole body scan.
    Hung MC, Wu HS, Kao CH, Chen WK, Changlai SP.
    Endocr Res; 2003 May; 29(2):169-75. PubMed ID: 12856803
    [Abstract] [Full Text] [Related]

  • 8. [Patients treated for differentiated thyroid cancer with negative 131I whole-body scans and elevated thyroglobulin levels: a possible course].
    Gutiérrez Cardo AL, Rodríguez Rodríguez JR, Borrego Dorado I, Navarro González E, Tirado Hospital JL, Vázquez Albertino R.
    Rev Esp Med Nucl; 2007 May; 26(3):138-45. PubMed ID: 17524307
    [Abstract] [Full Text] [Related]

  • 9. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
    Chung JK, So Y, Lee JS, Choi CW, Lim SM, Lee DS, Hong SW, Youn YK, Lee MC, Cho BY.
    J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
    [Abstract] [Full Text] [Related]

  • 10. Diagnostic Capabilities of MRI Versus 18F FDG PET-CT in Postoperative Patients with Thyroglobulin Positive, 131I-negative Local Recurrent or Metastatic Thyroid Cancer.
    Samanci C, Onal Y, Sager S, Asa S, Ustabasioglu FE, Alis D, Akman C, Sonmezoglu K.
    Curr Med Imaging Rev; 2019 Jun; 15(10):956-964. PubMed ID: 32008523
    [Abstract] [Full Text] [Related]

  • 11. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P, Kuhn-Lansoy C, Edet-Sanson A, Hapdey S, Modzelewski R, Hitzel A, d'Anjou J, Basuyau JP.
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [Abstract] [Full Text] [Related]

  • 12. Positron emission tomography for the detection of metastases of differentiated thyroid carcinoma.
    Lips P, Comans EF, Hoekstra OS, van der Poest Clement E, van Mourik JC, Teule GJ.
    Neth J Med; 2000 Oct; 57(4):150-6. PubMed ID: 11006491
    [Abstract] [Full Text] [Related]

  • 13. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B, Paone G, Klain M, Storto G, Nicolai E, D'Amico D, Della Morte AM, Pace L, Salvatore M.
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [Abstract] [Full Text] [Related]

  • 14. [F-18-fluordeoxyglucose positron emission tomography on patients with differentiated thyroid cancer who present elevated human serum thyroglobulin levels and negative I-131 whole body scan].
    Ruiz Franco-Baux JV, Borrego Dorado I, Gómez Camarero P, Rodríguez Rodríguez JR, Vázquez Albertino RJ, Navarro González E, Astorga Jiménez R.
    Rev Esp Med Nucl; 2005 Mar; 24(1):5-13. PubMed ID: 15701340
    [Abstract] [Full Text] [Related]

  • 15. Comparison of (18)F-FDG, (131)I-Na, and (201)Tl in diagnosis of recurrent or metastatic thyroid carcinoma.
    Shiga T, Tsukamoto E, Nakada K, Morita K, Kato T, Mabuchi M, Yoshinaga K, Katoh C, Kuge Y, Tamaki N.
    J Nucl Med; 2001 Mar; 42(3):414-9. PubMed ID: 11337516
    [Abstract] [Full Text] [Related]

  • 16. Initial experience in use of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in thyroid carcinoma patients with elevated serum thyroglobulin but negative iodine-131 whole body scans.
    Ong SC, Ng DC, Sundram FX.
    Singapore Med J; 2005 Jun; 46(6):297-301. PubMed ID: 15902358
    [Abstract] [Full Text] [Related]

  • 17. Increasing the yield of recombinant thyroid-stimulating hormone-stimulated 2-(18-fluoride)-flu-2-deoxy-D-glucose positron emission tomography-CT in patients with differentiated thyroid carcinoma.
    Prestwich RJ, Viner S, Gerrard G, Patel CN, Scarsbrook AF.
    Br J Radiol; 2012 Oct; 85(1018):e805-13. PubMed ID: 22972977
    [Abstract] [Full Text] [Related]

  • 18. Is [18F]-2-fluoro-2-deoxy-d-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake?
    Giammarile F, Hafdi Z, Bournaud C, Janier M, Houzard C, Desuzinges C, Itti R, Sassolas G, Borson-Chazot F.
    Eur J Endocrinol; 2003 Oct; 149(4):293-300. PubMed ID: 14514343
    [Abstract] [Full Text] [Related]

  • 19. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
    Bannas P, Derlin T, Groth M, Apostolova I, Adam G, Mester J, Klutmann S.
    Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
    [Abstract] [Full Text] [Related]

  • 20. Use of 99mTc-sestamibi SPECT/CT when conventional imaging studies are negative for localizing suspected recurrence in differentiated thyroid cancer: a method and a lesson for clinical management.
    Wu D, Ylli D, Gomes Lima CJ, Lee W, Burman KD, Wartofsky L, Van Nostrand D.
    Endocrine; 2018 Oct; 62(1):57-63. PubMed ID: 29797211
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.